Implementation of Patient-reported Outcome Measures into Health Care for Men with Localized Prostate Cancer

Overview

Journal Nat Rev Urol

Specialty Urology

Date 2022 Mar 9

PMID 35260844

Authors

Udit Singhal

Ted A Skolarus

John L Gore

Matthew G Parry

Ronald C Chen

Julie Nossiter

Alan Paniagua-Cruz

Arvin K George

Paul Cathcart

Jan van der Meulen

Daniela A Wittmann

Affiliations

Soon will be listed here.

Abstract

Measuring treatment-related quality of life (QOL) has become an increasingly requisite component of delivering high-quality care for patients with prostate cancer. Patient-reported outcome measures (PROMs) have, therefore, become an important tool for understanding the adverse effects of radical prostate cancer treatment and have been widely integrated into clinical practice. By providing real-time symptom monitoring and improved clinical feedback to patients and providers, PRO assessment has led to meaningful gains in prostate cancer care delivery and quality improvement worldwide. By providing an avenue for benchmarking, collaboration and population health monitoring, PROMs have delivered substantial improvements beyond providing individual symptom feedback. However, multilevel barriers exist that need to be addressed before the routine implementation of PROMs is achieved. Improvements in collection, interpretation, standardization and reporting will be crucial for the continued implementation of PROM instruments in prostate cancer pathways.

Citing Articles

Efficiency of evidence-based collaborative nursing on complications, negative emotions and quality of live in radical prostatectomy.

Wu X, Zang X Am J Transl Res. 2025; 17(1):349-357.

PMID: 39959190 PMC: 11826179. DOI: 10.62347/DZDL1914.

[Patient-reported outcomes-the role of the patient's subjective perspective for research and clinical care].

Dinkel A, Jahnen M Urologie. 2024; 63(9):886-892.

PMID: 39110186 PMC: 11343820. DOI: 10.1007/s00120-024-02405-4.

Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate Cancer.

Ross A, Brewer K, Hudgens S, Brown B, Fallick M, de Paauw-Holt S Adv Ther. 2024; 41(8):3076-3088.

PMID: 38861216 PMC: 11263404. DOI: 10.1007/s12325-024-02888-9.

Application of Patient-Reported Outcome Measurements in Adult Tumor Clinical Trials in China: Cross-Sectional Study.

Jia Y, Li Q, Zhang X, Yan Y, Yan S, Li S J Med Internet Res. 2024; 26:e45719.

PMID: 38718388 PMC: 11112474. DOI: 10.2196/45719.

Selecting patient-reported outcome measures for a patient-facing technology.

Raj P, Cho Y, Jiang Y, Gong Y JAMIA Open. 2023; 6(4):ooad104.

PMID: 38098479 PMC: 10719077. DOI: 10.1093/jamiaopen/ooad104.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Litwin M, Lubeck D, Henning J, Carroll P . Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol. 1998; 159(6):1988-92. DOI: 10.1016/S0022-5347(01)63222-1. View

Sonn G, Sadetsky N, Presti J, Litwin M . Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol. 2009; 182(5):2296-302. DOI: 10.1016/j.juro.2009.07.027. View

Silva F . Quality of life in prostatic carcinoma. Eur Urol. 1993; 24 Suppl 2:113-7. DOI: 10.1159/000474401. View

Fromme E, Eilers K, Mori M, Hsieh Y, Beer T . How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004; 22(17):3485-90. DOI: 10.1200/JCO.2004.03.025. View

Wilson K, Dowling A, Abdolell M, Tannock I . Perception of quality of life by patients, partners and treating physicians. Qual Life Res. 2001; 9(9):1041-52. DOI: 10.1023/a:1016647407161. View

Lee P, Alexander K, Hammill B, Pasquali S, Peterson E . Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001; 286(6):708-13. DOI: 10.1001/jama.286.6.708. View

Sveistrup J, Mortensen O, Bjorner J, Engelholm S, Munck Af Rosenschold P, Petersen P . Prospective assessment of the quality of life before, during and after image guided intensity modulated radiotherapy for prostate cancer. Radiat Oncol. 2016; 11(1):117. PMC: 5015215. DOI: 10.1186/s13014-016-0689-4. View

Litwin M, Hays R, Fink A, Ganz P, Leake B, Brook R . The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998; 36(7):1002-12. DOI: 10.1097/00005650-199807000-00007. View

10.

Wei J, Dunn R, Litwin M, Sandler H, Sanda M . Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000; 56(6):899-905. DOI: 10.1016/s0090-4295(00)00858-x. View

11.

Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B . The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007; 45(5 Suppl 1):S3-S11. PMC: 2829758. DOI: 10.1097/01.mlr.0000258615.42478.55. View

12.

Hedestig O, Sandman P, Tomic R, Widmark A . Living after radical prostatectomy for localized prostate cancer: a qualitative analysis of patient narratives. Acta Oncol. 2005; 44(7):679-86. DOI: 10.1080/02841860500326000. View

13.

Bokhour B, Clark J, Inui T, Silliman R, Talcott J . Sexuality after treatment for early prostate cancer: exploring the meanings of "erectile dysfunction". J Gen Intern Med. 2001; 16(10):649-55. PMC: 1495277. DOI: 10.1111/j.1525-1497.2001.00832.x. View

14.

Wittmann D, Carolan M, Given B, Skolarus T, An L, Palapattu G . Exploring the role of the partner in couples' sexual recovery after surgery for prostate cancer. Support Care Cancer. 2014; 22(9):2509-15. DOI: 10.1007/s00520-014-2244-x. View

15.

Bernat J, Wittman D, Hawley S, Hamstra D, Helfand A, Haggstrom D . Symptom burden and information needs in prostate cancer survivors: a case for tailored long-term survivorship care. BJU Int. 2015; 118(3):372-8. PMC: 4835263. DOI: 10.1111/bju.13329. View

16.

Sanders S, Pedro L, Bantum E, Galbraith M . Couples surviving prostate cancer: Long-term intimacy needs and concerns following treatment. Clin J Oncol Nurs. 2006; 10(4):503-8. DOI: 10.1188/06.CJON.503-508. View

17.

Whiting P, Moore T, Jameson C, Davies P, Rowlands M, Burke M . Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU Int. 2016; 118(2):193-204. DOI: 10.1111/bju.13499. View

18.

Sanda M, Cadeddu J, Kirkby E, Chen R, Crispino T, Fontanarosa J . Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2017; 199(3):683-690. DOI: 10.1016/j.juro.2017.11.095. View

19.

Hoffman K, Penson D, Zhao Z, Huang L, Conwill R, Laviana A . Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2020; 323(2):149-163. PMC: 6990712. DOI: 10.1001/jama.2019.20675. View

20.

Chen R, Chang P, Vetter R, Lukka H, Stokes W, Sanda M . Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst. 2014; 106(7). PMC: 4192044. DOI: 10.1093/jnci/dju132. View